Search Result

Results for "

PARP Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PARP (155) Akt (1) Anaplastic lymphoma kinase (ALK) (1) Androgen Receptor (2) Apoptosis (45) Autophagy (6) Bacterial (1) c-Met/HGFR (1) c-Myc (1) Caspase (6) CDK (4) DNA/RNA Synthesis (2) Drug Metabolite (1) Dynamin (1) Endogenous Metabolite (4) Epigenetic Reader Domain (3) HDAC (4) Histone Demethylase (1) Histone Methyltransferase (2) HIV (1) IGF-1R (1) Influenza Virus (1) Isotope-Labeled Compounds (2) JNK (1) Microtubule/Tubulin (5) Mitophagy (4) Nucleoside Antimetabolite/Analog (7) P-glycoprotein (2) PI3K (2) PPAR (1) PROTACs (4) Proteasome (1) Reverse Transcriptase (1) ROS Kinase (1) Sirtuin (1) STAT (1) Topoisomerase (2) VEGFR (1)
By Research Areas:	Cancer (158) Cardiovascular Disease (6) Infection (2) Inflammation/Immunology (10) Metabolic Disease (3) Neurological Disease (10)
Click Chemistry:	Alkynes (2)

188

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: PARP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10885

A-620223 succinate ABT-472	PARP	Cancer
A-620223 succinate (ABT-472) is an orally available poly(ADP-ribose) polymerase (PARP) inhibitor. A-620223 succinate (ABT-472) exhibits very good potency against the PARP-1 enzyme with a K_i value of 8 nM and an EC₅₀ value of 3 nM in whole cell assay, making it useful in cancer research .

HY-157165

Tubulin/PARP-IN-1	Microtubule/Tubulin PARP	Cancer
Tubulin/PARP-IN-1 (compound 14) is a dual PARP-tubulin inhibitor with activity against endometrial cancer. *Tubulin/PARP*-IN-1 inhibits PARP and tubulin with IC₅₀s of 74 nM (PARP1), 109 nM (PARP2), and 1.4 μM (Microtubule/Tubulin), respectively. Tubulin/PARP-IN-1 can induce apoptosis and autophagy and cause cell cycle arrest in the G2/M phase .

HY-160409

TopBP1-IN-1

Others Cancer

TopBP1-IN-1 is a TopBP1 inhibitor. TopBP1-IN-1 has a synergistic effect with PARP inhibitors. TopBP1-IN-1 has antitumor activity .

TopBP1-IN-1	Others	Cancer
TopBP1-IN-1 is a TopBP1 inhibitor. TopBP1-IN-1 has a synergistic effect with *PARP* inhibitors. TopBP1-IN-1 has antitumor activity .

HY-120115

PARPi-FL Olaparib-bodipy FL	PARP	Cancer
PARPi-FL is a small molecule and fluorescent inhibitor of *PARP1*. PARPi-FL is a highly selective probe and can be used as an imaging agent to detect glioblastomas in vivo .

HY-W424851

DPQ hydrochloride 6,7-Dimethoxy-2-(1-piperazinyl)-4-quinazolinamine hydrochloride	PARP	Infection Inflammation/Immunology
DPQ hydrochloride (6, 7-dimethoxy-2 -(1-piperazinyl)-4-quinazolinamine hydrochloride) is a *PARP1* inhibitor, with IC₅₀ value of 40 nM. DPQ hydrochloride has anti-inflammatory and antiviral activity. DPQ hydrochloride is used to study acute lung injury .

HY-13540

E7016 GPI 21016	PARP	Cancer
E7016 (GPI 21016) is an orally available *PARP* inhibitor. E7016 can enhance tumor cell radiosensitivity in vitro and in vivo through the inhibition of DNA repair. E7016 acts as a potential anticancer agent .

HY-148566

OUL232	PARP	Cancer
OUL232 is a potent inhibitor of mono-ARTs PARP7, PARP10, PARP11, PARP12, PARP14, and *PARP15. OUL232 is the most potent PARP10* inhibitor described to date (IC₅₀=7.8 nM), as well as the first *PARP12* inhibitor ever reported .

HY-157137

PARP1-IN-17	PARP Caspase Apoptosis	Cancer
PARP1-IN-17 is a *PARP-1* inhibitor (IC₅₀ = 19.24 nM for *PARP-1* and = 32.58 nM for PARP-2) and induce apoptosis. PARP1-IN-17 shows excellent anti-proliferative activity .

HY-153590

PARP-1-IN-4	PARP	Cancer
PARP-1-IN-4 is a *PARP-1* inhibitor. PARP-1-IN-4 has inhibitory activity against PARP-1 with IC₅₀ value of 302 μM. PARP-1-IN-4 can be used for the research of lung adenocarcinoma .

HY-147886

PARP1-IN-11	PARP	Cancer
PARP1-IN-11 (compound 49) is a potent *PARP1* inhibitor with IC₅₀ value of 0.082 µM. PARP1-IN-11 shows complete inhibition of PARP2 and substantially inhibits PARP3, TNKS1 and TNKS2 .

HY-14478

UPF 1069

1 Publications Verification

PARP Cancer

UPF 1069 is a PARP inhibitor, with IC₅₀s of 8 and 0.3 μM for PARP-1 and PARP-2, respectively.
HY-102035

PARP-2-IN-1

PARP Cancer

PARP-2-IN-1 is a potent and selective PARP-2 inhibitor with an IC₅₀ of 11.5 nM.

UPF 1069 1 Publications Verification	PARP	Cancer
UPF 1069 is a *PARP* inhibitor, with IC₅₀s of 8 and 0.3 μM for PARP-1 and PARP-2, respectively.

PARP-2-IN-1	PARP	Cancer
PARP-2-IN-1 is a potent and selective *PARP-2* inhibitor with an IC₅₀ of 11.5 nM.

HY-143398

PARP10/15-IN-1	PARP	Cancer
PARP10/15-IN-1 (compound 8l) is a potent inhibitor of dual inhibitor of *PARP10* and *PARP15, with IC₅₀s of 160 nM and 370 nM, respectively. PARP*10/15-IN-1 can be used for cancer .

HY-105253

PARP-2/1-IN-2	PARP	Neurological Disease
PARP-2/1-IN-2 (Compound 4a), the enantiomer of Veliparib (HY-10129), is a potent *PARP* inhibitor with K_is of 2 and 5 nM against *PARP-2* and *PARP-1, respectively. PARP-2/1-IN-2 has an EC₅₀ of 3 nM in a cell based assay of PARP* activity .

HY-155122

PARP-1-IN-13	PARP	Cancer
PARP-1-IN-13 (Compound 19c) is a *PARP-1* inhibitor (IC₅₀: 26 nM). PARP-1-IN-13 inhibits DNA single-strand breakage repair and aggravates DNA double-strand breakage. PARP-1-IN-13 promotes the apoptosis of cancer cells through the mitochondrial apoptosis pathway .

HY-148754

PARP10-IN-3	PARP	Cancer
PARP10-IN-3 is a selective mono‐ADP‐ribosyltransferase *PARP10* inhibitor with an IC₅₀ of 480 nM for human PARP10. PARP10-IN-3 reveals potent inhibition on *PARP2* and *PARP15* with IC₅₀s of 1.7 μM for human PARP2 and human PARP15, respectively .

HY-149800

PARP-1-IN-3	PARP Apoptosis Caspase	Cancer
PARP-1-IN-3, a benzamide derivative, is a potent *PARP-1* inhibitor with IC₅₀ values of 0.25 nM and 2.34 nM for PARP-1 and PARP-2, respectively. PARP-1-IN-3 induces apoptosis and arrest cell cycle at G2/M phase. PARP-1-IN-3 can be used in research of cancer .

HY-10617

Rucaparib phosphate 30+ Cited Publications AG-014699 phosphate; PF-01367338 phosphate	PARP	Cancer
Rucaparib (AG014699) phosphate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib phosphate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib phosphate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-10617A

Rucaparib 30+ Cited Publications AG014699; PF-01367338	PARP	Cancer
Rucaparib (AG014699) is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research .

HY-10617D

Rucaparib acetate AG014699 acetate; PF-01367338 acetate	PARP	Cancer
Rucaparib (AG014699) acetate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib acetate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib acetate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-10617B

Rucaparib hydrochloride AG014699 hydrochloride; PF-01367338 hydrochloride	PARP	Cancer
Rucaparib (AG014699) hydrochloride is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib hydrochloride is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib hydrochloride has the potential for castration-resistant prostate cancer (CRPC) research .

HY-119653

AZ9482

PARP Cancer

AZ9482 is a triple PARP1/2/6 inhibitor, with IC₅₀ values of 1 nM, 1 nM and 640 nM for PARP1, PARP2 and PARP6, respectively .

AZ9482	PARP	Cancer
AZ9482 is a triple *PARP1/2/6* inhibitor, with IC₅₀ values of 1 nM, 1 nM and 640 nM for PARP1, PARP2 and PARP6, respectively .

HY-149398

PARP-1/2-IN-2	Apoptosis PARP CDK	Cancer
PARP-1/2-IN-2-IN-1 (Compound 12e) is a *PARP1/2/CDK12* inhibitor (IC₅₀: 34, 30 and 285 nM respectively). PARP-1/2-IN-2 inhibits DNA damage repair, promotes cell cycle arrest and apoptosis. PARP-1/2-IN-2 inhibits the growth of TNBC cells and TNBC xenograft tumor .

HY-102003

Rucaparib monocamsylate 2 Publications Verification AG014699 monocamsylate; PF-01367338 monocamsylate	PARP	Cancer
Rucaparib (AG014699) monocamsylate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib monocamsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib monocamsylate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-102003A

Rucaparib camsylate AG014699 camsylate; PF-01367338 camsylate	PARP	Cancer
Rucaparib (AG014699) camsylate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib camsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib camsylate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-10617C

Rucaparib tartrate AG-014699 tartrate; PF-01367338 tartrate	PARP	Cancer
Rucaparib (AG014699) tartrate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib tartrate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib tartrate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-155246

PARP1-IN-15	Apoptosis PARP	Cancer
PARP1-IN-15 (Compound 6) is a *PARP1* inhibitor. PARP1-IN-15 inhibits tankyrase (TNKS) and facilitates DNA double-strand breaks damage. PARP1-IN-15 induces tumor cell apoptosis. PARP1-IN-15 has anti-cancer activity in triple-negative breast cancer (TNBC) cells and TNBC patient-derived organoids. PARP1-IN-15 can be used for research of TNBC with or without BRCA1 mutations .

HY-132297A

PARP1-IN-5 dihydrochloride 1 Publications Verification	PARP	Cancer
PARP1-IN-5 dihydrochloride is a low toxicity, orally active, potent and selective *PARP-1* inhibitor (IC₅₀ =14.7 nM). PARP1-IN-5 dihydrochloride can be used for the research of cancer .

HY-132297

PARP1-IN-5

PARP Cancer

PARP1-IN-5 is a low toxicity, orally active, potent and selective PARP-1 inhibitor (IC₅₀ =14.7 nM). PARP1-IN-5 can be used for the research of cancer .
HY-151609

PARP7-IN-12

PARP Cancer

PARP7-IN-12 is a potent PARP7 Inhibitor with an IC₅₀ value of 7.836 nM. PARP7-IN-12 can be used in research of cancer .

PARP1-IN-5	PARP	Cancer
PARP1-IN-5 is a low toxicity, orally active, potent and selective *PARP-1* inhibitor (IC₅₀ =14.7 nM). PARP1-IN-5 can be used for the research of cancer .

PARP7-IN-12	PARP	Cancer
PARP7-IN-12 is a potent *PARP7* Inhibitor with an IC₅₀ value of 7.836 nM. PARP7-IN-12 can be used in research of cancer .

HY-148753

PARP10-IN-2	PARP	Cancer
PARP10-IN-2 is a potent mono‐ADP‐ribosyltransferase *PARP10* inhibitor with an IC₅₀ of 3.64 μM for human PARP10. PARP10-IN-2 reveals potent inhibition on *PARP2* and *PARP15* with IC₅₀s of 27 μM and 11 μM for human PARP2 and human PARP15, respectively .

HY-145328

PARP-1/2-IN-1

PARP Others

PARP-1/2-IN-1 is a potent PARP-1/2 inhibitor with IC₅₀ of 0.51 nM and 23.11 nM, respectively.
HY-163081

PARP7-IN-17

PARP Cancer

PARP7-IN-17 is a potent inhibitor of PARP7 with IC₅₀ of 4.5 nM that has oral bioavailability. PARP7-IN-17 displays antitumor effect .
HY-162114

PARP1-IN-18

PARP Cancer

PARP1-IN-18 (compound 25) is a potent PARP1 inhibitor with an IC₅₀ value of 2.7 nM. PARP1-IN-18 has anticancer effects .

PARP-1/2-IN-1	PARP	Others
PARP-1/2-IN-1 is a potent PARP-1/2 inhibitor with IC₅₀ of 0.51 nM and 23.11 nM, respectively.

PARP7-IN-17	PARP	Cancer
PARP7-IN-17 is a potent inhibitor of *PARP7* with IC₅₀ of 4.5 nM that has oral bioavailability. PARP7-IN-17 displays antitumor effect .

PARP1-IN-18	PARP	Cancer
PARP1-IN-18 (compound 25) is a potent *PARP1* inhibitor with an IC₅₀ value of 2.7 nM. PARP1-IN-18 has anticancer effects .

HY-151625

PARP-2-IN-3	PARP Apoptosis	Cancer
PARP-2-IN-3 (Compound 12) is a potent *PARP-2* inhibitor with an IC₅₀ of 0.07 μM. PARP-2-IN-3 induces apoptosis and necrosis in cancer cells. PARP-2-IN-3 shows appropriate predicted pharmacokinetic parameters and oral bioavailability .

HY-145749

PARPYnD	PARP	Cancer
PARPYnD is a *PARP* enzyme photoaffinity probe (AfBP) based on the triple *PARP1/2/6* inhibitor AZ9482 (HY-119653), which induces breast cancer Formation of multipolar spindles (MPS) in cells. PARPYnD inhibits PAPR wih IC₅₀ of 38 nM (PARP1), 6 nM (PARP2), 230 nM (PARP6), respectively. PARPYnD enriches recombinant PARP6 incorporated into cell lysates and inhibits PARP6 in cell-free assays, but it does not label PARP6 in intact cells .

HY-13536

AZD-2461

5+ Cited Publications

PARP Cancer

AZD-2461 is a potent PARP inhibitor, with IC₅₀s of 5 nM, 2 nM and 200 nM for PARP1, PARP2 and PARP3, respectively.

AZD-2461 5+ Cited Publications	PARP	Cancer
AZD-2461 is a potent *PARP* inhibitor, with IC₅₀s of 5 nM, 2 nM and 200 nM for PARP1, PARP2 and PARP3, respectively.

HY-157490

PARP/HDAC-IN-1	PARP HDAC	Cancer
PARP/HDAC-IN-1 (compound B102) is a potent dual inhibitor of *PARP* and HDAC. PARP/HDAC-IN-1 inhibits *PARP1, PARP2* and HDAC1 with IC₅₀s of 19.01, 2.13, 1690 nM, respectively .

HY-162172

PARP7-IN-18	PARP	Cancer
Parp7-in-18 (Compund 8) is a selective *PARP7* inhibitor with an IC₅₀ of 0.11 nM. PARP7-IN-18 exhibits good anticancer activity and pharmacokinetic properties .

HY-146502

PARP10/15-IN-3	PARP Apoptosis	Cancer
PARP10/15-IN-3 (Compound 8a) is a potent *PARP10* and *PARP15* dual inhibitor with IC₅₀ values of 0.14 µM and 0.40 µM against PARP10 and PARP15, respectively. PARP10/15-IN-3 is able to enter cells and rescue cells from apoptosis .

HY-151624

PARP-2-IN-2	PARP Apoptosis	Cancer
PARP-2-IN-2 (compound 27) is a *PARP‑2* inhibitor with an IC₅₀ value of 0.057 µM. PARP-2-IN-2 induces cell cycle arrest and apoptosis of MCF-7 breast cancer cells. PARP-2-IN-2 can be used for the research of cancer .

HY-162349

PARP7/HDACs-IN-1	HDAC PARP	Cancer
PARP7/HDACs-IN-1 (compound 9l) is a dual-target inhibitor targeting *PARP7/HDAC* with anti-tumor activity. PARP7/HDACs-IN-1 inhibits different subtypes of PARPs and HDACs with IC₅₀s of 83.3 nM (PARP1), 3.1 nM (PARP7), 35 nM (HDAC1), 30.3 nM (HDAC2), 35.4 nM (HDAC3), and 6.4 nM respectively. (HDAC6) . br/ .

HY-144338

PARP1/BRD4-IN-1	Epigenetic Reader Domain PARP Apoptosis DNA/RNA Synthesis	Cancer
PARP1/BRD4-IN-1 is a potent and high selective *PARP1/BRD4* inhibitor (IC₅₀s of 49 and 202 nM in PARP1 and BRD4, respectively). PARP1/BRD4-IN-1 represses the expression and activity of PARP1 and BRD4 to synergistically inhibit the malignant growth of pancreatic cancer cells .

HY-157212

PARP-1/Proteasome-IN-1	Apoptosis PARP Proteasome	Cancer
PARP-1/Proteasome-IN-1 (compound 42i) is a dual PARP-1 and proteasome inhibitor with significant inhibitory effects on breast cancer. *PARP-1/Proteasome*-IN-1 can downregulate the expression of BRCA1 and RAD51 to inhibit homologous recombination repair function and induce apoptosis .

HY-146501

PARP10/15-IN-2	PARP Apoptosis	Cancer
PARP10/15-IN-2 (Compound 8h) is a potent *PARP10* and *PARP15* dual inhibitor with IC₅₀ values of 0.15 µM and 0.37 µM against PARP10 and PARP15, respectively. PARP10/15-IN-2 is able to enter cells and rescue cells from apoptosis .

HY-10129

Veliparib

25+ Cited Publications

ABT-888
PARP Autophagy Cancer

Veliparib (ABT-888) is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with K_is of 5.2 and 2.9 nM, respectively .

Veliparib 25+ Cited Publications ABT-888	PARP Autophagy	Cancer
Veliparib (ABT-888) is a potent *PARP* inhibitor, inhibiting *PARP1* and *PARP2* with K_is of 5.2 and 2.9 nM, respectively .

HY-125218

PARP11 inhibitor ITK7 ITK7	PARP	Cancer
PARP11 inhibitor ITK7 (ITK7) is a potent and selective *PARP11* inhibitor. PARP11 inhibitor ITK7 can potently inhibit PARP11 with an IC₅₀ value of 14 nM. PARP11 inhibitor ITK7 can be used for the research of cellular localization . PARP11 inhibitor ITK7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-149001

PARP1-IN-9	PARP	Cancer
PARP1-IN-9 (Compound 5c) is a PARP1 inhibitor with an IC₅₀ of 30.51 nM. PARP1-IN-9 induces cell apoptosis and shows anticancer activity. PARP1-IN-9 has higher potency than Olaparib (HY-10162) .

HY-108632

BYK204165	PARP	Cancer
BYK204165 is a potent and selective *PARP1* inhibitor. BYK204165 inhibits cell-free recombinant human PARP-1 (hPARP-1) with a pIC₅₀ of 7.35 (pK_i=7.05), and murine PARP-2 (mPARP-2) with a pIC₅₀ of 5.38, respectively. BYK204165 displays 100-fold selectivity for PARP-1 .

HY-117889

PARP14 inhibitor H10	PARP Apoptosis	Cancer
PARP14 inhibitor H10, compound H 10, is a selective inhibitor against *PARP14* (IC₅₀=490 nM), over other PARPs (≈24 fold over PARP1). PARP14 inhibitor H10 induces caspase-3/7-mediated cell apoptosis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113432

Nudifloramide 2PY	Alkaloids Structural Classification Classification of Application Fields Other disease Source classification Disease markers Pyridine Alkaloids Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite PARP
Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro .

HY-122935

Nigranoic acid	Infection Triterpenes Classification of Application Fields Terpenoids Source classification Plants Schisandraceae Disease Research Fields Schisandra chinensis (Turcz.) Baill.	HIV Reverse Transcriptase
Nigranoic acid is a triterpenoid separated from Schisandra chinensis. Nigranoic acid inhibits HIV-1 reverse transcriptase. Nigranoic acid exhibits protective effects on brain through PARP/AIF signaling pathway in cerebral ischemia-reperfusion animal model .

HY-Z0283

Benzamide Benzenecarboxamide; Phenylamide	Structural Classification Alkaloids Human Gut Microbiota Metabolites Classification of Application Fields Other Alkaloids Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite PARP
Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-W748509

Pipernonaline	Piper longum Linn. Structural Classification Alkaloids Piperidine Alkaloids Source classification Piperaceae Plants	Caspase Apoptosis
Pipernonaline is a piperine derivative with antiprostate cancer activity. Pipernonaline inhibits the proliferation of androgen-dependent/independent LNCaP/PC-3 prostate cells. Pipernonaline activates caspase-3 and promotes procaspase-3/PARP cleavage. Pipernonaline also mediates reactive oxygen species (ROS) production, increased intracellular Ca(2+), and mitochondrial membrane depolarization .

Cat. No.	Product Name	Chemical Structure

HY-Z0283S

Benzamide-15N

Benzamide- ¹⁵N is a ¹⁵N-labeled Benzamide. Benzamide inhibits poly(ADP-ribose) polymerase (PARP)[1][2].

HY-16106S

Talazoparib-13C,d4
Talazoparib- ¹³C,d4 is ¹³C and deuterated labeled Talazoparib (HY-16106). Talazoparib is an orally active PARP 1/2 inhibitor with Ki values of 1.2 nM and 0.87 nM for inhibiting PARP1 and PARP2 enzymatic activities, respectively. Has anti-tumor activity.

HY-10162S1

Olaparib-d8
Olaparib-d₈ is the deuterium labeled Olaparib (AZD2281). Olaparib is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4].

HY-10162S3

Olaparib-d4-1
Olaparib-d₄-1 is the deuterium labeled Olaparib. Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4].

HY-10162S

Olaparib-d5

Olaparib-d₅ is a deuterium labeled Olaparib. Olaparib is a potent and oral PARP inhibitor[1].

HY-113432S

Nudifloramide-d3
Nudifloramide-d₃ (2PY-d3) is the deuterium labeled Nudifloramide. Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

PARP Inhibitors

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products